Illumina, Inc.

NASDAQ:ILMN

Medical - Diagnostics & Research

Healthcare
$210.01 +1.23%

+$1.95 today

Market cap
$31.75B
Beta
1.49
P/E (TTM)
28.9
EPS (TTM)
$5.58
52W Low $88.00High $177.22

Volume 1.63M

Average 1.65M

ILMN Pre-Tax Margin

Income before tax as a percentage of revenue.

Illumina, Inc.NASDAQ: ILMN

Pre-Tax Margin · Q2 FY2026 · quarter ended Jun 2026

Pre-tax margin narrows to 22.4%

Pre-tax margin was 22.4% in Q2 FY2026, down 6.5 pp from a year earlier. On a trailing-twelve-month basis it was 22.6%, down 10.0 pp year over year. Over 3 fiscal years it widened by 119.6 pp.

Context

  • Pre-tax margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
22.4%+8.0 pp QoQ
Last fiscal yearDec 2025
25.0%+52.0 pp YoY
LTMJun 2026
22.6%-10.0 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-6.5 pp——
1 year+52.0 pp——
3 years+119.6 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
25.0%
Year-over-year change
+52.0pp

Pre-Tax Margin vs competitors

How ILMN compares with its peers on the latest reported figures

  • ILMN's LTM Jun 2026 pre-tax margin of 22.6% is the highest of the 11 companies compared; the peer median is -30.7%.
  • Its year-over-year change of -10.0 pp is the 8th highest of 11, against a peer median of +2.2 pp.
  • Over three fiscal years its change of +119.6 pp compares with a peer median of +40.1 pp.
ILMN Competitors Peer median
Pre-Tax Margin for ILMN and competitors
Company Period LTM level YoY 3-year change
ILMNIllumina, Inc.LTM Jun 202622.6% -10.0 pp+119.6 pp
BLLNBillionToOne, Inc.LTM Jun 20269.5% +24.1 pp—
NEONeoGenomics, Inc.LTM Jun 2026-7.1% +8.2 pp+16.1 pp
NTRANatera, Inc.LTM Jun 2026-9.3% +3.6 pp+55.0 pp
TXG10x Genomics, Inc.LTM Sep 2026-10.5% +0.9 pp+25.2 pp
WGSGeneDx Holdings Corp.LTM Jun 2026-23.4% -23.8 pp+249.9 pp
GHGuardant Health, Inc.LTM Sep 2026-38.0% +6.1 pp+102.8 pp
MYGNMyriad Genetics, Inc.LTM Mar 2026-48.2% -33.0 pp-27.2 pp
PACBPacific Biosciences of California, Inc.LTM Mar 2026-79.8% +351.9 pp-96.4 pp
SOPHSOPHiA GENETICS S.A.LTM Mar 2026-98.1% -1.7 pp+82.6 pp
PSNLPersonalis, Inc.LTM Mar 2026-148.1% -50.0 pp—
Peer median (excluding ILMN) -30.7%+2.2 pp+40.1 pp

Competitors are the stored peer set for ILMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Jan 2022
FY2022
Jan 2023
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.53B4.58B4.5B4.37B4.34B
Cost of Revenue1.37B1.61B1.76B1.51B1.45B
Gross Profit3.15B2.97B2.74B2.86B2.89B
Gross Margin69.7%64.8%60.9%65.4%66.7%
Research & Development1.19B1.32B1.35B1.17B951M
Selling, General & Admin2.09B1.3B1.61B1.09B1.08B
Operating Expenses3.28B7.15B3.81B3.69B2.03B
Depreciation & Amortization251M394M432M354M270M
EBITDA1.2B(3.92B)(608M)(725M)1.46B
EBITDA Margin26.4%-85.4%-13.5%-16.6%33.6%
Operating Income(123M)(4.18B)(1.07B)(833M)864M
Operating Margin-2.7%-91.2%-23.7%-19.1%19.9%
Interest Income011M58M46M40M
Interest Expense61M26M77M100M101M
Other Income / Expenses1.01B(157M)(48M)(346M)222M
Income Before Tax884M(4.34B)(1.12B)(1.18B)1.09B
Pre-Tax Margin19.5%-94.6%-24.8%-27.0%25.0%
Income Tax Expense122M68M44M44M236M
Net Income762M(4.4B)(1.16B)(1.22B)850M
Net Margin16.8%-96.1%-25.8%-28.0%19.6%
EPS (Basic)5.08(28.05)(7.35)(7.69)5.48
EPS (Diluted)5.05(28.05)(7.35)(7.69)5.45
Weighted Avg Shares150M157M158M159M155M
Weighted Avg Shares (Diluted)151M157M158M159M156M

Illumina, Inc.

NASDAQ:ILMN

Intrinsic Alpha fair value

Locked

Current Price

$210.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.